Radiotherapy Improves Survival in NSCLC After Oligoprogression on Immunotherapy: A Cohort Study-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Radiotherapy Improves Survival in NSCLC After Oligoprogression on Immunotherapy: A Cohort Study

Published:2024-05 Issue: Volume: Page:100695
ISSN:2666-3643
Container-title:JTO Clinical and Research Reports
language:en
Short-container-title:JTO Clinical and Research Reports

Author:

Brown Lauren Julia^ORCID,Ahn Julie,Gao Bo,Gee Harriet,Nagrial Adnan,Pires da Silva Inês,Hau Eric

Publisher

Elsevier BV

Reference31 articles.

1. Five-year outcomes with pembrolizumab versus chemotherapy for metastatic non–small-cell lung cancer with PD-L1 tumor proportion score ≥ 50%;Reck;J Clin Oncol,2021

2. Pembrolizumab plus chemotherapy in squamous non–small-cell lung cancer: 5-year update of the Phase III KEYNOTE-407 study;Novello;J Clin Oncol,2023

3. Pembrolizumab plus pemetrexed and platinum in nonsquamous non–small-cell lung cancer: 5-year outcomes from the phase 3 KEYNOTE-189 study;Garassino;J Clin Oncol,2023

4. Oligoprogressive non-small-cell lung cancer under treatment with PD-(L)1 Inhibitors;Rheinheimer;Cancers (Basel),2020

5. Characterisation and classification of oligometastatic disease: a European Society for Radiotherapy and Oncology and European Organisation for Research and Treatment of Cancer consensus recommendation;Guckenberger;Lancet Oncol,2020

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3